We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vogelxo (testosterone) gel

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vogelxo (testosterone) gel

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Vogelxo is a topical gel formulation of testosterone. Endogenous androgens, including testosterone, are responsible for the normal growth and development of the primary and secondary male sexual characteristics.

    Vogelxo is specifically indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).

    Vogelxo is supplied as a gel for topical administration. The recommended starting dose for adult males is 50 mg of testosterone (one tube or one packet or 4 pump actuations) applied topically once daily at approximately the same time each day. It should be applied to clean, dry, intact skin of the shoulders and/or upper arms. Do not apply Vogelxo to the genitals or abdomen. If morning pre-dose serum testosterone concentration is below the normal range, increase dose to 100 mg. Pe-dose serum testosterone concentration should be assessed periodically. Patients should wash hands with soap and water immediately after applying Vogelxo and cover application site(s) with clothing after gel has dried.

    Clinical Results

    FDA Approval

    The FDA approval was based on a randomized multicenter, multi-dose, active and placebo controlled 90-day study in 406 adult males with morning testosterone levels ≤300 ng/dL. The study was double-blind for the doses of testosterone gel and placebo, but open label for the non­scrotal testosterone transdermal system. During the first 60 days, subjects were evenly randomized to testosterone gel 50 mg, testosterone gel 100 mg, placebo gel, or testosterone transdermal system. At Day 60, subjects receiving testosterone gel were maintained at the same dose, or were titrated up or down within their treatment group, based on 24-hour averaged serum testosterone concentration levels obtained on Day 30. Of 192 hypogonadal men who were appropriately titrated with testosterone gel and who had sufficient data for analysis, 74% achieved an average serum testosterone level within the normal range (300 to 1,000 ng/dL) on treatment Day 90. 

    Side Effects

    Adverse effects associated with the use of Vogelxo may include, but are not limited to, the following:

    • application site reactions
    • increased hematocrit

    Mechanism of Action

    Vogelxo is a topical gel formulation of testosterone. Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution.

    Additional Information

    For additional information regarding Vogelxo or the absence or deficiency of endogenous  testosterone, please visit www.upsher-smith.com

    Approval Date: 2014-06-01
    Date Created: 2014-06-12 01:11:17
    Company Name: Upsher-Smith
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing